Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of monohydroxyethylrutoside in healthy volunteers.
Willems AM, Bruynzeel AM, Kedde MA, van Groeningen CJ, Bast A, van der Vijgh WJ. Willems AM, et al. Among authors: van groeningen cj, van der vijgh wj. Cancer Chemother Pharmacol. 2006 May;57(5):678-84. doi: 10.1007/s00280-005-0083-7. Epub 2005 Sep 1. Cancer Chemother Pharmacol. 2006. PMID: 16136309 Clinical Trial.
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A, van der Vijgh WJ, van Groeningen CJ. Bruynzeel AM, et al. Among authors: van groeningen cj, van der vijgh wj, van der hoeven jj. Br J Cancer. 2007 Oct 22;97(8):1084-9. doi: 10.1038/sj.bjc.6603994. Epub 2007 Oct 16. Br J Cancer. 2007. PMID: 17940501 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G. Boven E, et al. Among authors: van groeningen cj, van der vijgh wj. Br J Cancer. 2005 May 9;92(9):1636-43. doi: 10.1038/sj.bjc.6602553. Br J Cancer. 2005. PMID: 15841080 Free PMC article. Clinical Trial.
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ. Kroep JR, et al. Among authors: van groeningen cj, van der vijgh wj, van der born k. Cancer Chemother Pharmacol. 2006 Oct;58(4):509-16. doi: 10.1007/s00280-006-0191-z. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16523337 Clinical Trial.
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Honkoop AH, van der Wall E, Feller N, Schuurhuis GJ, van der Vijgh WJ, Boven E, van Groeningen CJ, Giaccone G, Hoekman K, Vermorken JB, Wagstaff J, Pinedo HM. Honkoop AH, et al. Among authors: van groeningen cj, van der vijgh wj, van der wall e. Ann Oncol. 1997 Oct;8(10):957-62. doi: 10.1023/a:1008259518263. Ann Oncol. 1997. PMID: 9402167 Free article.
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ. Peters GJ, et al. Among authors: van gennip ah, van groeningen cj, van kuilenburg ab. Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. doi: 10.1007/s00280-003-0617-9. Epub 2003 May 9. Cancer Chemother Pharmacol. 2003. PMID: 12739060 Clinical Trial.
167 results